Co-Pay Assistance Program Expanded
How's this for some good news?
I am thriiled to announce that the Co-Pay Assistance Program through the Leukemia and Lymphoma Society has been expanded.
What does this mean for you? Qualified patients with chronic myelogenous leukemia and myeloma can now receive up to $5,000 in assistance from The Leukemia & Lymphoma Society's (LLS) Co-Pay Assistance Program. The aid helps offset prescription drug co-pays and other insurance-related expenses according to disease diagnosis. For more information, visit www.LLS.org/copay or call (877) 557-2672.
The LLS Co-Pay Assistance program is pleased to announce a new tool to help patients and providers submit online applications quickly and easily. The Co-Pay Assistance program provides financial assistance for health insurance payments and blood cancer treatment co-pay obligations to qualified patients. For more information, visit www.LLS.org/copay or call (877) 557-2672.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
